BioDlink International Co Ltd (01875.HK)価格

BioDlink International Co., Ltd. is clinical stage biopharmaceutical company, which engages in developing and commercializing oncology drugs and therapies. The company is headquartered in Suzhou, Jiangsu and currently employs 604 full-time employees. The company went IPO on 2019-11-08. The firm and its subsidiaries are primarily engaged in research, development, manufacturing, and marketing of anti-tumor drugs, contract development and manufacturing organization (CDMO) business and license-out of self-developed biological drugs in the People’s Republic of China. The firm owns a pipeline of oncology drug candidates, which include monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). The firm has built and established a fully integrated in-house platform of discovery, process development, quality management, pre-clinical and clinical development, as well as commercial-scale manufacturing facilities and sales and marketing capabilities. The firm mainly conducts its businesses in the domestic market.